Madhu Emani, MD
Medical Oncology · Huntersville, NCNPI 1053639880
Payments from drug & device makers
What this record shows
This record is dominated by grants: $120 of the $181 with a category attached, or 66.4%. AbbVie accounts for 66.4% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $134 and has fallen 88.0% since, to $16 in 2024. That places this record below the midpoint for medical oncology clinicians in NC, where the typical reported total is $1,025.
Across 5 payments — averaging $36.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$120
- E.r. Squibb & Sons, L.L.C.$61
What the payments were for
- Grants$12066%
- Education$6134%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 1 | $120 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$181 in reported general payments places this provider in the 20th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 34 | $550,403 |
| BrukinsaZanubrutinib | 37 | $529,948 |
| RevlimidLenalidomide | 32 | $441,536 |
| XtandiEnzalutamide | 13 | $190,349 |
| ImbruvicaIbrutinib | 11 | $184,420 |
| XareltoRivaroxaban | 36 | $39,486 |
| Abiraterone Acetate | 13 | $31,516 |
| EliquisApixaban | 35 | $26,532 |
| Hydroxyurea | 72 | $2,203 |
| Tamoxifen Citrate | 53 | $1,386 |
| Dexamethasone | 40 | $827 |
| Letrozole | 50 | $822 |
| Prochlorperazine Maleate | 39 | $689 |
| Acyclovir | 39 | $632 |
| Ondansetron OdtOndansetron | 26 | $393 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Huntersville
- Thomas LeblancDurham$1.7M
- David RizzieriCharlotte$714K
- Raghava InduruAlbemarle$625K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Andrew ArmstrongDurham$377K
- John StricklerDurham$319K
- Neal ReadyDurham$309K
- Thomas StinchcombeChapel Hill$281K
- Steven SorscherWinston Salem$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.